Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy.

Bordron A, Bagacean C, Mohr A, Tempescul A, Bendaoud B, Deshayes S, Dalbies F, Buors C, Saad H, Berthou C, Pers JO, Renaudineau Y.

Oncotarget. 2018 Aug 3;9(60):31590-31605. doi: 10.18632/oncotarget.25657. eCollection 2018 Aug 3.

2.

Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1.

Berger J, Vigan M, Pereira B, Nguyen TT, Froissart R, Belmatoug N, Dalbiès F, Masseau A, Rose C, Serratrice C, Pers YM, Bertchansky I, Camou F, Bengherbia M, Bourgne C, Caillaud C, Pettazzoni M, Berrahal A, Stirnemann J, Mentré F, Berger MG.

Clin Pharmacokinet. 2019 Apr;58(4):469-482. doi: 10.1007/s40262-018-0708-8.

PMID:
30128966
3.

Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study).

Le Calloch R, Lacut K, Le Gall-Ianotto C, Nowak E, Abiven M, Tempescul A, Dalbies F, Eveillard JR, Ugo V, Giraudier S, Guillerm G, Lippert E, Berthou C, Ianotto JC.

Haematologica. 2018 Apr;103(4):607-613. doi: 10.3324/haematol.2017.180448. Epub 2017 Dec 15.

4.

Incidence and impact of atrial arrhythmias on thrombotic events in MPNs.

Mahé K, Delluc A, Chauveau A, Castellant P, Mottier D, Dalbies F, Berthou C, Guillerm G, Lippert E, Ianotto JC.

Ann Hematol. 2018 Jan;97(1):101-107. doi: 10.1007/s00277-017-3164-x. Epub 2017 Nov 21.

PMID:
29164292
5.

Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.

Stirnemann J, Rose C, Serratrice C, Dalbies F, Lidove O, Masseau A, Pers YM, Baron C, Belmatoug N.

Orphanet J Rare Dis. 2015 May 13;10:62. doi: 10.1186/s13023-015-0275-0.

6.

[Transfusion-transmitted bacterial infection of a apheresis platelet concentrate with Streptococcus gallolyticus: Analysis of one case].

Le Niger C, Dalbies F, Narbonne V, Hery-Arnaud G, Virmaux M, Léostic C, Hervé F, Liétard C.

Transfus Clin Biol. 2014 Jun;21(3):107-10. doi: 10.1016/j.tracli.2014.05.001. Epub 2014 Jun 13. French.

PMID:
24934685
7.

Imatinib mesylate induces massive and nonspecific aminoaciduria in CML patients.

Ianotto JC, Tempescul A, Amet Y, Grall P, Dalbies F, Eveillard JR, Guillerm G, Berthou C.

Am J Hematol. 2012 Apr;87(4):437-9. doi: 10.1002/ajh.23113. Epub 2012 Jan 28. No abstract available.

8.

[Systemic microsporidiosis and toxoplasmosis in a patient with T prolymphocytic leukemia].

Jamet D, Quinio D, Moalic E, Ianotto JC, Dalbies F, Guillerm G, Marion V, Berthou C, Nevez G.

Med Mal Infect. 2009 Jun;39(6):406-8. doi: 10.1016/j.medmal.2008.10.018. Epub 2008 Nov 28. French.

PMID:
19046839
9.

A combination therapy with fludarabine, mitoxantrone and rituximab induces complete immunophenotypical remission in B-cell prolymphocytic leukaemia.

Tempescul A, Feuerbach J, Ianotto JC, Dalbies F, Marion V, Le Bris MJ, De Braekeleer M, Berthou C.

Ann Hematol. 2009 Jan;88(1):85-8. doi: 10.1007/s00277-008-0541-5. Epub 2008 Jul 25. No abstract available.

PMID:
18654781
10.

Prolonged molecular remission in advanced phase of chronic myeloid leukemia using combination of imatinib and high-dose chemotherapy.

Saulnier PJ, Dalbiès F, Berthou C, Guilhot F, Bourmeyster N, Chomel JC, Thuran A.

Leuk Lymphoma. 2008 Apr;49(4):815-6. doi: 10.1080/10428190801930514. No abstract available.

PMID:
18398751

Supplemental Content

Loading ...
Support Center